Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) have been used to treat NSCLC since 2003 with great success in patients with EGFR mutations [4–6], which made physicians pay more attention to “individualized treatment”. This evidence concerns the gene EGFR and non-small cell lung carcinoma.